Plasma miR-21 is a novel diagnostic biomarker for biliary tract cancer

Cancer Science

Volumn 104, Issue 12, 2013, Pages 1626-1631

  Kishimoto, Tomoya ^a   Eguchi, Hidetoshi ^a   Nagano, Hiroaki ^a   Kobayashi, Shogo ^a   Akita, Hirofumi ^a   Hama, Naoki ^a   Wada, Hiroshi ^a   Kawamoto, Koichi ^a   Tomokuni, Akira ^a   Tomimaru, Yoshito ^a   Umeshita, Koji ^a   Doki, Yuichiro ^a   Mori, Masaki ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; MICRORNA 21;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BILIARY TRACT CANCER; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

AGED; BILIARY TRACT NEOPLASMS; CA-19-9 ANTIGEN; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84889578050     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12300     Document Type: Article

References (36)

1. Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology 2005; 128: 1655-67.
2. Deng FT, Li YX, Ye L, Tong L, Yang XP, Chai XQ. Hilar inflammatory pseudotumor mimicking hilar cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2010; 9: 219-21.
3. Van Beers BE. Diagnosis of cholangiocarcinoma. HPB (Oxford) 2008; 10: 87-93.
4. Desa LA, Akosa AB, Lazzara S, Domizio P, Krausz T, Benjamin IS. Cytodiagnosis in the management of extrahepatic biliary stricture. Gut 1991; 32: 1188-91.
5. Kurzawinski T, Deery A, Dooley J, Dick R, Hobbs K, Davidson B. A prospective controlled study comparing brush and bile exfoliative cytology for diagnosing bile duct strictures. Gut 1992; 33: 1675-7.
6. Davidson B, Varsamidakis N, Dooley J et al. Value of exfoliative cytology for investigating bile duct strictures. Gut 1992; 33: 1408-11.
7. Marrelli D, Caruso S, Pedrazzani C et al. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg 2009; 198: 333-9.
8. Sandanayake NS, Sinclair J, Andreola F et al. A combination of serum leucine-rich alpha-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures. Br J Cancer 2011; 105: 1370-8.
9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-97.
10. Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 2006; 66: 7390-4.
11. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-66.
12. Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006.
13. Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-8.
14. Lawrie CH, Gal S, Dunlop HM et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008; 141: 672-5.
15. Liu R, Chen X, Du Y et al. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem 2012; 58: 610-8.
16. Roth C, Rack B, Muller V, Janni W, Pantel K, Schwarzenbach H. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res 2010; 12: R90.
17. Tsujiura M, Ichikawa D, Komatsu S et al. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 2010; 102: 1174-9.
18. Zhang C, Wang C, Chen X et al. Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. Clin Chem 2010; 56: 1871-9.
19. Kanaan Z, Rai SN, Eichenberger MR et al. Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann Surg 2012; 256: 544-51.
20. Komatsu S, Ichikawa D, Takeshita H et al. Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer 2011; 105: 104-11.
21. Tomimaru Y, Eguchi H, Nagano H et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol 2012; 56: 167-75.
22. Asangani IA, Rasheed SA, Nikolova DA et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008; 27: 2128-36.
23. Tomimaru Y, Eguchi H, Nagano H et al. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-alpha/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer 2010; 103: 1617-26.
24. Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res 2011; 39: 7223-33.
25. Chen L, Yan HX, Yang W et al. The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma. J Hepatol 2009; 50: 358-69.
26. Selaru FM, Olaru AV, Kan T et al. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology 2009; 49: 1595-601.
27. Simon R, Radmacher MD, Dobbin K, McShane LM. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 2003; 95: 14-8.
28. Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 2000; 95: 204-7.
29. Qin XL, Wang ZR, Shi JS, Lu M, Wang L, He QR. Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA. World J Gastroenterol 2004; 10: 427-32.
30. Paraskevi A, Theodoropoulos G, Papaconstantinou I, Mantzaris G, Nikiteas N, Gazouli M. Circulating MicroRNA in inflammatory bowel disease. J Crohns Colitis 2012; 6: 900-4.
31. Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 2010; 101: 2087-92.
32. Arroyo JD, Chevillet JR, Kroh EM et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011; 108: 5003-8.
33. Simpson RJ, Lim JW, Moritz RL, Mathivanan S. Exosomes proteomic insights and diagnostic potential. Expert Rev Proteomics 2009; 6: 267-83.
34. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem 2010; 285: 17442-52.
35. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008; 110: 13-21.
36. Yamamichi N, Shimomura R, Inada K et al. Locked nucleic acid in situ hybridization analysis of miR-21 expression during colorectal cancer development. Clin Cancer Res 2009; 15: 4009-16.